28. **Boulet LP**, Lemiere C, Archambault F, *et al.* Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. *Chest* 2006;**129**:661–8.
29. **Chaudhuri R**, Livingston E, McMahon AD, *et al.* Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. *Am J Respir Crit Care Med* 2006;**174**:127–33.
30. **Robbins RA**, Millatmal T, Lassi K, *et al.* Smoking cessation is associated with an increase in exhaled nitric oxide. *Chest* 1997;**112**:313–8.
31. **Su Y**, Han W, Giraldo C, *et al.* Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. *Am J Respir Cell Mol Biol* 1998;**19**:819–25.
32. **Jones KL**, Bryan TW, Jinkins PA, *et al.* Superoxide released from neutrophils causes a reduction in nitric oxide gas. *Am J Physiol* 1998;**275**:L1120–6.
33. **Green RH**, Brightling CE, Woltmann G, *et al.* Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. *Thorax* 2002;**57**:875–9.
34. **Douwes J**, Gibson P, Pekkanen J, *et al.* Non-eosinophilic asthma: importance and possible mechanisms. *Thorax* 2002;**57**:643–8.
35. **Simpson JL**, Scott R, Boyle MJ, *et al.* Inflammatory subtypes in asthma: assessment and identification using induced sputum. *Respirology* 2006;**11**: 54–61.

Lung alert

Utility of serum and sputum calprotectin as a biomarker for CF exacerbation

Monitoring inflammation and diagnosing pulmonary exacerbation in cystic fibrosis (CF) remains difficult as the usual biomarkers of inflammation are often not very helpful and there is still no accepted definition for a CF exacerbation. This study looked at the possibility of serum and sputum calprotectin as a new biomarker for monitoring pulmonary exacerbations in CF.

It was hypothesised that serum and sputum calprotectin will change informatively during the CF exacerbation. Twenty-seven patients completed the study. Sputum was tested for calprotectin, interleukin 8 (IL-8), myeloperoxidase (MPO) and neutrophils at the beginning and the end of treatment. Serum was tested for calprotectin, white cell count, C-reactive protein (CRP) and vascular endothelial growth factor (VEGF). Case notes were reviewed a year after completion of the study to calculate the time to the next exacerbation.

Sputum calprotectin was significantly reduced ($p < 0.05$) with treatment. MPO and IL-8 also decreased with treatment but the trend was not significant. In serum, calprotectin, CRP and VEGF were all reduced significantly with treatment ($p = 0.002$, $p = 0.002$ and $p = 0.013$, respectively). Serum calprotectin and CRP were both negatively correlated with the forced expiratory volume in 1 s (FEV_1) but the correlation was much stronger for calprotectin. For a calprotectin level of $\geq 9.1 \mu\text{g}$, the median time to the next exacerbation was 70 days, whereas for a level of < 9.1 it was 112 days. CRP failed to show a difference in median time to next exacerbation with the cut-off value of 10.

This study shows that calprotectin is a better biomarker for inflammation in the CF lung and could be useful in monitoring the exacerbations and response to treatment. It can also be useful in predicting the time to the next exacerbation.

► **Gray RD**, Imrie M, Boyd AC, *et al.* Sputum and serum calprotectin are useful biomarkers during CF exacerbation. *J Cyst Fibros* 2010;**9**:193–8.

Irfan Shafiq

Correspondence to Dr Irfan Shafiq, Cystic Fibrosis Unit, Southampton General Hospital, Tremona road, Southampton SO16 6YD, UK; irfanshafiq@gmail.com

Published Online First 21 October 2010

Thorax 2010;**65**:1044. doi:10.1136/thx.2010.149641